Myopic Choroidal Neovascularization
📧 Sign up to get email alerts when something new happens for Myopic Choroidal Neovascularization.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV [Phase 2]
Phase 2 study evaluating the usability of the SB11 prefilled syringe (ranibizumab biosimilar) in participants with wet age-related macular d…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Deep Learning-Based OCTA Quantification and Modeling for Predicting Long-Term Anti-VEGF Efficacy in mCNV
A clinical trial investigating deep learning-based OCTA quantification and modeling to predict long-term anti-VEGF efficacy in myopic choroi…
-
CLINICAL_TRIALS other · 2025-06-06Clinical Trial Update: The Treatment Burden of Myopic Choroidal Neovascularization
A sponsor-led trial evaluating the treatment burden of anti-VEGF therapy for myopic choroidal neovascularization is currently not yet recrui…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients [EARLY_Phase 1]
Phase 1 trial evaluating intravitreal aflibercept 8 mg for resistant diabetic macular edema, retinal vein occlusion, and myopic choroidal ne…
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: VISUPRIME® Eye Drops [NA]
Clinical trial update noting the completion of a VISUPRIME Eye Drops study sponsored by VISUfarma SpA for several retinal diseases.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-10-03FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved Biogen's BYOOVIZ (ranibizumab-nuna) via a supplemental application, providing an additional approval for this ranibizumab biosi…
-
FDA approval · 2023-06-16FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen Inc.
-
FDA approval · 2022-08-15FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approves Biogen's BYOOVIZ (ranibizumab-nuna) via a supplemental application, authorizing the biosimilar for the same ocular indications …
-
FDA approval · 2022-06-09FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, authorizing its use as a biosimilar to ranibizumab.
-
CLINICAL_TRIALS withdrawal · 2015-09-02Clinical Trial Update: Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia [NA]
Clinical trial evaluating intravitreal pegaptanib for myopic choroidal neovascularization has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2014-06-26Clinical Trial Update: VEGF and PEDF in Patients With Myopic Choroidal Neovascularization
This update reports on a completed clinical trial investigating VEGF and PEDF levels in patients with myopic choroidal neovascularization.
-
CLINICAL_TRIALS trial_result · 2014-01-10Clinical Trial Update: Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization [Phase 4]
Phase 4 clinical trial update evaluating aflibercept intravitreal injections for myopic choroidal neovascularization.
-
CLINICAL_TRIALS trial_result · 2014-01-01Clinical Trial Update: Ranibizumab for Myopic Neovascularization [Phase 4]
A Phase 4 clinical trial evaluating ranibizumab for myopic choroidal neovascularization is underway, with the trial status currently unknown…
-
CLINICAL_TRIALS trial_result · 2008-11-25Clinical Trial Update: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization [Phase 4]
A Phase 4 clinical trial evaluating intravitreal bevacizumab for myopic choroidal neovascularization has completed.